- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01941654
ATOM_local Ablative Therapy
June 18, 2020 updated by: CCTU, Chinese University of Hong Kong
A Single-arm Phase II Study to Determine the Efficacy of Preemptive Local Ablative Therapy to Residual Metabolic Active Oligo-metastases in Those EGFR Mutation Positive Non-small Cell Lung Cancer Patients Who Have Achieved a Good Partial Response With First-line EGFR TKI (ATOM)
To determine the efficacy of preemptive local ablative therapy in NSCLC patients with activating EGFR mutation who have oligometastatic residual metabolic-active disease after first-line EGFR TKI, as measured by PFS rate at 1 year from the trial enrollment.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
18
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Hong Kong, Hong Kong
- Department of Clinical Oncology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Pathologically confirmed UICC 7th edition Stage IIIB (not amenable for curative intent local radiotherapy)/IV (metastatic or recurrent) non-small cell carcinoma of lung
- Documented activating EGFR mutation (exon 19 deletion or exon 21 L858R only) in tumor tissues
- Treated with first-line EGFR TKI for 3 months and achieved good radiological partial response that was documented with a CT scan
- Not more than 4 residual metabolic active (SUVmax > 2.5) metastatic sites left on the screening PET-CT scan. (one bone metastatic site is regarded as a single site, mediastinal/ hilar lymph nodes in close proximity and possible to be treated in an acceptable volume is regarded as one lesion)
- The shortest diameter of the lesion must be ≥ 1cm and is amenable to local ablative therapy
- Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2
- Age ≥ 18 years
- Pleural or pericardial effusion at diagnosis is allowed only if it has resolved on CT scan after 3-month EGFR TKI treatment
- Brain metastasis at diagnosis is allowed if it has been treated either surgically or with radiotherapy and there is no radiological progression on follow-up CT scan. The patient is neurologically stable for at least 1 week after cessation of steroid treatment
Adequate organ function as defined by the following criteria:
- Serum alanine transaminase ≤ 3 x upper limit of normal (ULN) or ≤ 5 x ULN if liver function abnormalities are due to liver metastases
- Total bilirubin ≤ 1.5 x ULN
- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
- Platelets count ≥ 100 x 109/L
- Creatinine clearance > 45ml/min
- Written informed consent that is consistent with ICH-GCP guidelines
Exclusion Criteria:
- Prior chemotherapy is not allowed except adjuvant chemotherapy for completely resected early staged non-small cell lung cancer and it has been at least 12 months before the start of EGFR TKI treatment
- Prior radiotherapy is not allowed except brain irradiation
- Leptomeningeal carcinomatosis
- Lymphangitis carcinomatosis of lung
- Prior or concomitant malignancy at other sites is not allowed except treated non-metastatic non-melanoma skin cancer, ductal carcinoma-in-situ of breast and carcinoma-in-situ of cervix with curative intent
- Uncontrolled active infection or medical condition (e.g. uncontrolled hypertension, unstable angina, congestive heart failure [≥ NYHA Class II], uncontrolled arrhythmia, myocardial infarction or cerebrovascular accident within the past 6 month)
- Pre-existing interstitial lung disease
- Woman of child-bearing potential or male patient is unwilling to use adequate birth control method prior to the study entry, for the duration of study participation and for at least 2 months after the EGFR TKI treatment has ended.
- Pregnant and Lactating female patient
- Non-compliance to the study procedure
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: preemptive local ablative therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
PFS rate at 1 year
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival
Time Frame: 2 years
|
2 years
|
Progression-free survival
Time Frame: 2 years
|
2 years
|
radiologic change on PET-CT scan 3 months after SABR
Time Frame: 3 months
|
3 months
|
Number of Participants with Adverse Events as a Measure of safety
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Kwok Chi LAM, FRCP, Prince of Wales Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 18, 2013
Primary Completion (Actual)
December 31, 2017
Study Completion (Actual)
May 28, 2020
Study Registration Dates
First Submitted
September 3, 2013
First Submitted That Met QC Criteria
September 10, 2013
First Posted (Estimate)
September 13, 2013
Study Record Updates
Last Update Posted (Actual)
June 18, 2020
Last Update Submitted That Met QC Criteria
June 18, 2020
Last Verified
June 1, 2020
More Information
Terms related to this study
Other Study ID Numbers
- LUN060
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NSCLC
-
Shanghai Henlius BiotechCompleted
-
The Netherlands Cancer InstituteEnrolling by invitation
-
Centre Oscar LambretUniversity Hospital, LilleTerminated
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompleted
-
Bio-Thera SolutionsCompleted
-
Jiangsu Province Nanjing Brain HospitalRecruiting
-
TYK Medicines, IncRecruiting
-
Radboud University Medical CenterPfizer; ImaginAb, Inc.; University Hospital TuebingenNot yet recruitingNSCLCGermany, Netherlands
-
Beta Pharma, Inc.Completed
Clinical Trials on preemptive local ablative therapy
-
University of California, DavisNational Cancer Institute (NCI)RecruitingOligoprogressive | Non-small Cell Lung Cancer | Small-cell Lung CancerUnited States
-
University of California, DavisNational Cancer Institute (NCI)RecruitingOligoprogressive | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Small Bowel Cancer | Intrahepatic Cholangiocarcinoma | Gall Bladder Cancer | Extrahepatic Cholangiocarcinoma | Appendiceal Cancer | Biliary Cancer | Gastroesophageal-junction CancerUnited States
-
University of California, DavisNational Cancer Institute (NCI)RecruitingSarcoma | Breast Cancer | Head and Neck Cancer | Oligoprogressive | Other CancerUnited States
-
University of California, DavisNational Cancer Institute (NCI)RecruitingRenal Cell Carcinoma | Oligoprogressive | Prostate Cancer | Urothelial CarcinomaUnited States
-
Gitte Fredberg Persson MD PhDRecruitingSurgery | Oligometastatic Disease | Radiotherapy | Metastases | Stereotactic Radiation | Ablation TechniquesDenmark
-
Memorial Sloan Kettering Cancer CenterRecruitingNon-small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | Minimal Residual Disease | NSCLC Stage IV | Nsclc | Metastatic Non Small Cell Lung CancerUnited States
-
Universitaire Ziekenhuizen KU LeuvenRecruitingNon-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor ReceptorBelgium
-
Technische Universität DresdenRecruitingOligometastatic Disease | Prostatic Cancer, Castration-ResistantGermany
-
Australasian Gastro-Intestinal Trials GroupCancer Council Victoria; Walter and Eliza Hall Institute of Medical ResearchRecruitingColorectal Cancer | Oligometastatic DiseaseAustralia
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMalignant Liver NeoplasmUnited States